Commercial bioprocessing questions with Pratima Cherukuri, CSO

Scroll Down

In the Nov/Dec issue of European Pharmaceutical Manufacturer, Pratima Cherukuri, Chief Scientific Officer at Genezen answers vital questions surrounding bioprocessing at commercial scale and provides insight into the key challenges involved.

Read the full article here: European Pharmaceutical Manufacturer – Nov/Dec 2021

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more